{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:18Z","timestamp":1792839858950,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T00:00:00Z","timestamp":1468195200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s11926-016-0599-3","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T05:22:57Z","timestamp":1468214577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Neuromyelitis Optica (Devic\u2019s Syndrome): an Appraisal"],"prefix":"10.1007","volume":"18","author":[{"given":"Teresa M.","family":"Crout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura P.","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Majithia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"599_CR1","first-page":"1033","volume":"8","author":"E Devic","year":"1894","unstructured":"Devic E. Subacute myelitis complicated by optic neuritis [French]. Bull Med. 1894;8:1033\u20134.","journal-title":"Bull Med"},{"key":"599_CR2","first-page":"434","volume":"1","author":"E Devic","year":"1895","unstructured":"Devic E. Acute dorsolumbar myelitis with optic neuritis, autopsy [French]. Congr Fr Med. 1895;1:434\u20139.","journal-title":"Congr Fr Med"},{"key":"599_CR3","unstructured":"Gault F. De la neuromyelite optique aigue [thesis]. Lyon; 1894."},{"key":"599_CR4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","volume":"10","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8. The authors recount the history from origin and emphasize the need for updates in diagnosis and treatment.","journal-title":"J Neuroinflammation"},{"key":"599_CR5","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106\u201312.","journal-title":"Lancet"},{"issue":"9","key":"599_CR6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"2","key":"599_CR7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.410340211","volume":"34","author":"RN Mandler","year":"1993","unstructured":"Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic\u2019s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol. 1993;34(2):162\u20137.","journal-title":"Ann Neurol"},{"issue":"3","key":"599_CR8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/016164106X98260","volume":"28","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res. 2006;28(3):348\u201353.","journal-title":"Neurol Res"},{"issue":"Pt 7","key":"599_CR9","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain. 2002;125(Pt 7):1450\u201361.","journal-title":"Brain"},{"issue":"9451","key":"599_CR10","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106\u2013112.","journal-title":"Lancet"},{"issue":"Pt 11","key":"599_CR11","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(Pt 11):3072\u201380.","journal-title":"Brain"},{"issue":"Pt 5","key":"599_CR12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130(Pt 5):1235\u201343.","journal-title":"Brain"},{"issue":"8","key":"599_CR13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019\u201332.","journal-title":"Eur J Neurol"},{"issue":"3","key":"599_CR14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","volume":"75","author":"R Takano","year":"2010","unstructured":"Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010;75(3):208\u201316.","journal-title":"Neurology"},{"issue":"4","key":"599_CR15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","volume":"109","author":"SR Hinson","year":"2012","unstructured":"Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012;109(4):1245\u201350. This paper illustrates the possible pathogenic molecular mechanisms of NMO-IgG.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 5","key":"599_CR16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"SF Roemer","year":"2007","unstructured":"Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(Pt 5):1194\u2013205.","journal-title":"Brain"},{"issue":"20","key":"599_CR17","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","volume":"78","author":"MI Leite","year":"2012","unstructured":"Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012;78(20):1601\u20137. Multicenter study of 16 patients who had coexistence of MG and NMOSD suggesting possible association.","journal-title":"Neurology"},{"issue":"1","key":"599_CR18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","volume":"65","author":"SJ Pittock","year":"2008","unstructured":"Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78\u201383.","journal-title":"Arch Neurol"},{"issue":"7","key":"599_CR19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","volume":"21","author":"L Pandit","year":"2015","unstructured":"Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler J. 2015;21(7):845\u201353. A significant review article, which analyzed all peer-reviewed publications for incidence and prevalence, clinical phenotypes, and demographic features of NMO.","journal-title":"Mult Scler J"},{"key":"599_CR20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","volume":"76","author":"N Asgari","year":"2011","unstructured":"Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76:1589\u201395.","journal-title":"Neurology"},{"key":"599_CR21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079649","volume":"8","author":"F Aboul-Enein","year":"2013","unstructured":"Aboul-Enein F, Seifert-Held T, Mader S, et al. Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS ONE. 2013;8, e79649.","journal-title":"PLoS ONE"},{"key":"599_CR22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","volume":"256","author":"JA Cabrera-Gomez","year":"2009","unstructured":"Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, et al. An epidemiological study on neuromyelitis optica in Cuba. J Neurol. 2009;256:35\u201344.","journal-title":"J Neurol"},{"key":"599_CR23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","volume":"74","author":"N Collongues","year":"2010","unstructured":"Collongues N, Marignier R, Z\u00e9phir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74:736\u201342.","journal-title":"Neurology"},{"key":"599_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","volume":"251","author":"A Ghezzi","year":"2004","unstructured":"Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic\u2019s NMO. J Neurol. 2004;251:47\u201352.","journal-title":"J Neurol"},{"key":"599_CR25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1212\/WNL.0b013e31824f8069","volume":"78","author":"SH Kim","year":"2012","unstructured":"Kim SH, Kim W, Li XF, et al. Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology. 2012;78:1179\u201385. The article includes 106 seropositive NMOSD patients out of 388 patients of inflammatory demyelinating illnesses and analyzes the clinical spectrum of neurologic manifestations and the disease course.","journal-title":"Neurology"},{"key":"599_CR26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology. 1999;53:1107\u201314.","journal-title":"Neurology"},{"key":"599_CR27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.autrev.2014.01.034","volume":"13","author":"T Drori","year":"2014","unstructured":"Drori T, Chapman J. Diagnosis and classification of neuromyelitis optica (Devic\u2019s syndrome). Autoimmun Rev. 2014;13:531\u20133. A significant review article that brings together the various historical diagnostic criteria.","journal-title":"Autoimmun Rev"},{"key":"599_CR28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17:1019\u201332. A significant systemic review article that reviewed all the available evidence on the NMO diagnosis, classification, and management as well as developed best clinical practice recommendations.","journal-title":"Eur J Neurol"},{"key":"599_CR29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389. Eighteen experts from nine countries developed the consensus criteria, making this a significant article, which incorporated all the available evidence and clarified nomenclature of the NMOSD.","journal-title":"Neurology"},{"key":"599_CR30","first-page":"1355","volume":"69","author":"K Suzuki","year":"2012","unstructured":"Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol. 2012;69:1355\u201359.","journal-title":"Arch Neurol"},{"key":"599_CR31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","volume":"77","author":"Y Kanamori","year":"2011","unstructured":"Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology. 2011;77:652\u201358.","journal-title":"Neurology"},{"key":"599_CR32","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/0883073812451495","volume":"27","author":"JM Tillema","year":"2012","unstructured":"Tillema JM, McKeon A. The spectrum of neuromyelitis optica (NMO) in childhood. J Child Neurol. 2012;27:1437\u201347.","journal-title":"J Child Neurol"},{"key":"599_CR33","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","volume":"80","author":"L Matthews","year":"2013","unstructured":"Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013;80:1330\u201337. The authors compared the scans of 44 AQP-4+ NMO patients with 50 MS patients to help distinguish these two disorders with similar clinical presentations.","journal-title":"Neurology"},{"key":"599_CR34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","volume":"63","author":"SJ Pittock","year":"2006","unstructured":"Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390\u201396.","journal-title":"Arch Neurol"},{"key":"599_CR35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneurol.2011.249","volume":"68","author":"KH Chan","year":"2011","unstructured":"Chan KH, Tse CT, Chung CP, et al. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011;68:1432\u201339.","journal-title":"Arch Neurol"},{"key":"599_CR36","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.1503\/cmaj.101213","volume":"184","author":"C White","year":"2012","unstructured":"White C, Leonard B, Patel A. Longitudinally extensive transverse myelitis: a catastrophic presentation of a flare-up of systemic lupus erythematosus. CMAJ. 2012;184:E197\u2013200.","journal-title":"CMAJ"},{"key":"599_CR37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1352458511406165","volume":"18","author":"JL Kitley","year":"2012","unstructured":"Kitley JL, Leite MI, George JS, Palace JA. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler. 2012;18:271\u201385.","journal-title":"Mult Scler"},{"key":"599_CR38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1756285611398939","volume":"4","author":"N Collongues","year":"2011","unstructured":"Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord. 2011;4:111\u201321. A significant review article that addresses the progress in the treatment of NMOSD and brings together the available options.","journal-title":"Ther Adv Neurol Disord"},{"key":"599_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1\u201316. Article from NEMOS in Germany, which reviewed all the available options for treatment of NMOSD and provided an evidence-based recommendation.","journal-title":"J Neurol"},{"key":"599_CR40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","volume":"130","author":"H Merle","year":"2012","unstructured":"Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012;130:858\u201362.","journal-title":"Arch Ophthalmol"},{"key":"599_CR41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"DJ Kimbrough","year":"2012","unstructured":"Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1:180\u20137. A well-established group of international experts wrote this review article about available options for treatment of NMOSD and provided a comprehensive analysis of options and a set of recommended consensus practices.","journal-title":"Mult Scler Relat Disord"},{"key":"599_CR42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77:659\u201366.","journal-title":"Neurology"},{"key":"599_CR43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","volume":"67","author":"DB Bichuetti","year":"2010","unstructured":"Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol. 2010;67:1131\u201336.","journal-title":"Arch Neurol"},{"key":"599_CR44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128\u201333.","journal-title":"Arch Neurol"},{"key":"599_CR45","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","volume":"71","author":"SY Huh","year":"2014","unstructured":"Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372\u201378. Multicenter retrospective analysis of 59 patients with NMOSD treated with MMF suggesting its effectiveness.","journal-title":"JAMA Neurol"},{"key":"599_CR46","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76:1310\u201315.","journal-title":"Neurology"},{"key":"599_CR47","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110\u201317. Retrospective case series in an institutional referral center for multiple sclerosis, including 30 patients with relapsing NMO or NMOSD treated with rituximab, suggesting its role in treatment of these disorders.","journal-title":"JAMA Neurol"},{"key":"599_CR48","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17:1225\u201330.","journal-title":"Mult Scler"},{"key":"599_CR49","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0883073814553974","volume":"30","author":"K Weinfurtner","year":"2015","unstructured":"Weinfurtner K, Graves J, Ness J, et al. Prolonged remission in neuromyelitis optica following cessation of rituximab treatment. J Child Neurol. 2015;30:1366\u201370.","journal-title":"J Child Neurol"},{"key":"599_CR50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72:989\u201395. Retrospective review of 100 patients with relapsing NMOSD treated with rituximab for at least 6\u00a0months from 2006 to 2015 at the institutional referral center highlighting its long-term response and genetic polymorphism.","journal-title":"JAMA Neurol"},{"key":"599_CR51","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","volume":"84","author":"J Kitley","year":"2013","unstructured":"Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84:918\u201321. Retrospective case series of 14 seropositive NMO and NMOSD treated with methotrexate suggesting its efficacy and tolerability.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"599_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-14-51","volume":"14","author":"RS Ramanathan","year":"2014","unstructured":"Ramanathan RS, Malhotra K, Scott T. Treatment of neuromyelitis optica\/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol. 2014;14(1):1\u20135. A retrospective chart review of nine patients with seropositive NMO\/NMOSD, treated with methotrexate suggested a positive role in treatment.","journal-title":"BMC Neurol"},{"key":"599_CR53","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","volume":"84","author":"P Cabre","year":"2013","unstructured":"Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013;84:511\u201316.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"599_CR54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71:324\u201330. A retrospective, 10-year, multicenter analysis of relapses in 90 patients with NMO and NMO spectrum disorder treated with azathioprine, mycophenolate, and\/or rituximab which suggests similar outcomes.","journal-title":"JAMA Neurol"},{"key":"599_CR55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","volume":"70","author":"BC Kieseier","year":"2013","unstructured":"Kieseier BC, St\u00fcve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013;70:390\u201393.","journal-title":"JAMA Neurol"},{"key":"599_CR56","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","volume":"82","author":"M Araki","year":"2014","unstructured":"Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82:1302\u201306. A prospective study of seven seropositive patients with NMO or NMOSD who had failed standard therapy and were treated with monthly tocilizumab for 1\u00a0year with a good response.","journal-title":"Neurology"},{"key":"599_CR57","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","volume":"72","author":"M Ringelstein","year":"2015","unstructured":"Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756\u201363. Retrospective observational study with median follow-up of 36\u00a0months in eight patients treated with tocilizumab suggested its efficacy.","journal-title":"JAMA Neurol"},{"key":"599_CR58","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554\u201362. Prospective open label study of 14 patients with NMO\/NMOSD treated with eculizumab suggested its efficacy.","journal-title":"Lancet Neurol"},{"key":"599_CR59","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","volume":"13","author":"C Papeix","year":"2007","unstructured":"Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13:256\u201359.","journal-title":"Mult Scler"},{"key":"599_CR60","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","volume":"75","author":"J Shimizu","year":"2010","unstructured":"Shimizu J, Hatanaka Y, Hasegawa M, et al. IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75:1423\u201327.","journal-title":"Neurology"},{"key":"599_CR61","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00415-013-6965-4","volume":"260","author":"M Jury\u0144czyk","year":"2013","unstructured":"Jury\u0144czyk M, Zaleski K, Selmaj K. Natalizumab and the development of extensive brain lesions in neuromyelitis optica. J Neurol. 2013;260:1919\u201321.","journal-title":"J Neurol"},{"key":"599_CR62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","volume":"18","author":"JH Min","year":"2012","unstructured":"Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18:113\u201315.","journal-title":"Mult Scler"},{"issue":"9","key":"599_CR63","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","volume":"69","author":"MA Mealy","year":"2012","unstructured":"Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176\u201380. A landmark study established a national multicenter NMO clinical consortium, enrolled 187 patients in the cohort of patients with NMO\/NMOSD in US, and reported initial demographic, clinical, and radiographic features.","journal-title":"Arch Neurol"},{"issue":"Pt 6","key":"599_CR64","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(Pt 6):1834\u201349.","journal-title":"Brain"},{"issue":"4","key":"599_CR65","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","volume":"114","author":"H Merle","year":"2007","unstructured":"Merle H, Olindo S, Bonnan M, Donnio A, Richer R, Smadja D, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007;114(4):810\u20135.","journal-title":"Ophthalmology"},{"issue":"10","key":"599_CR66","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","volume":"80","author":"P Cabre","year":"2009","unstructured":"Cabre P, Gonz\u00e1lez-Quevedo A, Bonnan M, Saiz A, Olindo S, Graus F, et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry. 2009;80(10):1162\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"599_CR67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archophthalmol.2007.26","volume":"126","author":"RM Papais-Alvarenga","year":"2008","unstructured":"Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126(1):12\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"599_CR68","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","volume":"60","author":"DM Wingerchuk","year":"2003","unstructured":"Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848\u201353.","journal-title":"Neurology"},{"issue":"3","key":"599_CR69","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"BG Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59(3):566\u20139.","journal-title":"Ann Neurol"},{"issue":"8","key":"599_CR70","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/1352458508092811","volume":"14","author":"B Weinstock-Guttman","year":"2008","unstructured":"Weinstock-Guttman B, Miller C, Yeh E, Stosic M, Umhauer M, Batra N, et al. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler. 2008;14(8):1061\u20137.","journal-title":"Mult Scler"},{"issue":"23","key":"599_CR71","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","volume":"70","author":"M Matiello","year":"2008","unstructured":"Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197.","journal-title":"Neurology"},{"issue":"14","key":"599_CR72","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","volume":"81","author":"Y Jiao","year":"2013","unstructured":"Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197\u2013204. One hundred and sixty-three patients with NMO\/NMOSD from Mayo clinic were studied and found to have a higher sensitivity of serological testing using recombinant AQP4 antigen versus tissue-based IIF for detecting AQP4-IgG.","journal-title":"Neurology"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-016-0599-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-016-0599-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-016-0599-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T23:53:55Z","timestamp":1568159635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-016-0599-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1007\/s11926-016-0599-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]},"article-number":"54"}}